Neurizon Therapeutics Limited has released a press release.
Phase II Canine Trial begins at University of Cambridge
Filed with ASX ·
6ix hasn’t read this filing yet.
Neurizon Therapeutics Limited on 6ix
Story so far
Earlier from Neurizon Therapeutics
- Epichem achieves ISO 9001 2015 certification
- MPL capsules shipped to centres in NSW & Qld for Phase II
- Appendix 4E & Full Year Statutory Accounts 2016
- Further Canine Trials to be Initiated in Australia
- IP exchange with UNSW consolidates MPL patent position
Later from Neurizon Therapeutics
- Phase II Strategy Update
- PharmAust Receives $406K R&D Rebate from ATO
- Appendix 4C - Quarterly Report & Company Update
- Appendix 4D & Financial Report - Dec 2016
- Dr Richard Hopkins Appointed as CEO of PharmAust
Follow Neurizon Therapeutics into a list and get an email when it puts out news.
Follow Neurizon Therapeutics